Evaluation of bottom‐up modeling of the blood–brain barrier to improve brain penetration prediction via physiologically based pharmacokinetic modeling
- 7 February 2023
- journal article
- research article
- Published by Wiley in Biopharmaceutics & Drug Disposition
- Vol. 44 (1) , 60-70
Abstract
Predicting the brain penetration of drugs has been notoriously difficult; however, recently, permeability‐limited brain models have been constructed. Lead optimization for central nervous system compounds often focuses on compounds that have low transporter efflux, where passive permeability could be a main driver in determining cerebrospinal fluid (CSF)/brain concentrations. The main objective of this study was to evaluate the translatability of passive permeability data generated from different in vitro systems and its impact on the prediction of human CSF/brain concentrations using physiologically‐based pharmacokinetic (PBPK) modeling. In vitro data were generated using gMDCK and parallel artificial membrane permeability assay‐blood–brain barrier for comparison and predictions using a quantitative structure‐activity relationship model were also evaluated. PBPK modeling was then performed for seven compounds with moderate‐high permeability and a range of efflux in vitro, and the CSF/brain mass concentrations and Kpuu were reasonably predicted. This work provides the first step of a promising approach using bottom‐up PBPK modeling for CSF/brain penetration prediction to support lead optimization and clinical candidate selection.Keywords
This publication has 22 references indexed in Scilit:
- Development of a Physiologically Based Pharmacokinetic Model for the Rat Central Nervous System and Determination of an In Vitro–In Vivo Scaling Methodology for the Blood–Brain Barrier Permeability of Two Transporter Substrates, Morphine and OxycodoneJournal of Pharmaceutical Sciences, 2012
- Comparison of brain capillary endothelial cell-based and epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) cell-based surrogate blood–brain barrier penetration modelsEuropean Journal of Pharmaceutics and Biopharmaceutics, 2012
- Quantitative Evaluation of the Impact of Active Efflux by P-Glycoprotein and Breast Cancer Resistance Protein at the Blood-Brain Barrier on the Predictability of the Unbound Concentrations of Drugs in the Brain Using Cerebrospinal Fluid Concentration as a SurrogateThe Journal of Pharmacology and Experimental Therapeutics, 2011
- Species Independence in Brain Tissue Binding Using Brain HomogenatesDrug Metabolism and Disposition, 2011
- How well can in vitro brain microcapillary endothelial cell models predict rodent in vivo blood–brain barrier permeability?European Journal of Pharmaceutical Sciences, 2011
- Comparison of blood–brain barrier permeability assays: in situ brain perfusion, MDR1-MDCKII and PAMPA-BBBJournal of Pharmaceutical Sciences, 2009
- Progress in Brain Penetration Evaluation in Drug Discovery and DevelopmentThe Journal of Pharmacology and Experimental Therapeutics, 2008
- Drug development for CNS disorders: strategies for balancing risk and reducing attritionNature Reviews Drug Discovery, 2007
- In vitro models for the blood–brain barrierToxicology in Vitro, 2005
- Passive Permeability and P-Glycoprotein-Mediated Efflux Differentiate Central Nervous System (CNS) and Non-CNS Marketed DrugsThe Journal of Pharmacology and Experimental Therapeutics, 2002